Patents Assigned to Ascendis Pharma A/S
-
Patent number: 10835677Abstract: An auto injector (4) for administering injection of a medicament from a cartridge (700) containing the medicament, the auto injector comprising: a cartridge receiver (300) with a cartridge receiver compartment (302) configured to receive a cartridge assembly (600) with at least one cartridge retention member (808) when inserted through a cartridge receiver opening (302) along a longitudinal axis; and an ejector (200) configured to support the cartridge assembly (600) by being suspended to move along the longitudinal direction and being spring-loaded in the direction opposite of the receiving direction.Type: GrantFiled: December 29, 2016Date of Patent: November 17, 2020Assignee: Ascendis Pharma A/SInventors: Paul Erik Fabricius, Flemming Madsen, Jan Olesen
-
Patent number: 10729778Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: January 27, 2017Date of Patent: August 4, 2020Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 10653795Abstract: The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament.Type: GrantFiled: April 16, 2014Date of Patent: May 19, 2020Assignee: Ascendis Pharma A/SInventors: Harald Rau, Nora Kaluza, Ulrich Hersel, Thomas Knappe, Burkhardt Laufer
-
Publication number: 20200046725Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer, and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: Ascendis Pharma A/SInventors: Felix Cleeman, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
-
Publication number: 20190262426Abstract: The present invention relates to a hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof. It further relates to a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug, its use as medicament for the treatment of a IL-1 mediated disease, methods of application of such hydrogel-linked IL-1ra prodrugs or pharmaceutical compositions, methods of treatment, and containers comprising the hydrogel-linked IL-1ra prodrugs or pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said hydrogel-linked IL-1ra prodrug or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: January 28, 2019Publication date: August 29, 2019Applicant: Ascendis Pharma A/SInventors: Harald Rau, Joachim Zettler, Ulrich Hersel, Nora Kaluza, Mathias Krusch, Tobias Voigt
-
Publication number: 20190216940Abstract: The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of prodrugs.Type: ApplicationFiled: May 25, 2016Publication date: July 18, 2019Applicants: Ascendis Pharma A/S, Ascendis Pharma Inc.Inventors: Harald Rau, Nicola Bisek, Samuel Weisbrod
-
Publication number: 20190105400Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: ApplicationFiled: January 27, 2017Publication date: April 11, 2019Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogoe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20190009028Abstract: An auto injector (4) for administering injection of a medicament from a cartridge containing the medicament, the auto injector (4) comprising: a housing (6); a cartridge receiver (300) with a cartridge receiver compartment (302) configured to receive a cartridge assembly (600), with at least one cartridge retention member (808), when inserted through a cartridge receiver opening (301) along a longitudinal axis (L) in a receiving direction; wherein the cartridge receiver (300) has a passage (316) through which the at least one cartridge retention member (808) travels at least in the receiving direction, and a member (312) preventing movement beyond a retention position in a direction opposite of the receiving direction; an elongated ejector (200) that is configured with: an ejector support face (204) for supporting the cartridge or cartridge assembly (600), a longitudinal ejector slot (228) extending towards the ejector support face (204) from an ejector rest portion (206); wherein the elongated ejector (200)Type: ApplicationFiled: December 29, 2016Publication date: January 10, 2019Applicant: Ascendis Pharma A/SInventors: Thorben Kvisgaard Jacobsen, Jan Olesen
-
Publication number: 20180312582Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.Type: ApplicationFiled: July 3, 2018Publication date: November 1, 2018Applicant: Ascendis Pharma A/SInventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
-
Patent number: 10040850Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.Type: GrantFiled: October 7, 2014Date of Patent: August 7, 2018Assignee: Ascendis Pharma A/SInventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
-
Patent number: 10029015Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: GrantFiled: May 8, 2015Date of Patent: July 24, 2018Assignee: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Patent number: 9913912Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.Type: GrantFiled: December 6, 2013Date of Patent: March 13, 2018Assignee: Ascendis Pharma A/SInventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge
-
Patent number: 9872864Abstract: The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.Type: GrantFiled: August 10, 2012Date of Patent: January 23, 2018Assignee: Ascendis Pharma A/SInventors: Kennett Sprogøe, Harald Rau, Ulrich Hersel, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 9855340Abstract: The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.Type: GrantFiled: October 8, 2013Date of Patent: January 2, 2018Assignee: Ascendis Pharma A/SInventors: Harald Rau, Tobias Voigt, Burkhardt Laufer, Nicola Bisek, Franziska Hahn, Thomas Knappe
-
Publication number: 20170224829Abstract: The present invention relates to novel prodrugs of primary or secondary amine- or hydroxyl-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs and the use of said prodrugs.Type: ApplicationFiled: August 4, 2015Publication date: August 10, 2017Applicant: Ascendis Pharma A/SInventors: Nicola BISEK, Harald RAU, Felix CLEEMANN, Thomas KNAPPE, Romy REIMANN
-
Publication number: 20170100490Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.Type: ApplicationFiled: December 20, 2016Publication date: April 13, 2017Applicant: Ascendis Pharma A/SInventors: Felix Cleeman, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
-
Patent number: 9561287Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: August 10, 2012Date of Patent: February 7, 2017Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20160257739Abstract: The present invention relates to compounds comprising a protecting group moiety-tag moiety conjugate, a method of purification and monoconjugates obtained from such method of purification.Type: ApplicationFiled: October 7, 2014Publication date: September 8, 2016Applicant: Ascendis Pharma A/SInventors: Harald Rau, Nicola Bisek, Thomas Knappe, Romy Reimann, Sebastian Stark, Samuel Weisbrod
-
Publication number: 20160089446Abstract: The present invention relates to a process for the preparation of a hydrogel suitable as carrier in a hydrogel-linked prodrug, to hydrogels obtainable from said process, the use of such hydrogel as a carrier in a hydrogel-linked prodrug and to hydrogel-linked prodrugs comprising a covalently conjugated hydrogel of the present invention. The hydrogel prodrug carrier has a reduced drug loading on the outside of the hydrogel carrier. This is achieved by reducing the number of functional groups of the hydrogel, in particular those at its surface.Type: ApplicationFiled: April 16, 2014Publication date: March 31, 2016Applicant: Ascendis Pharma A/SInventors: Ulrich HERSEL, Harald RAU, Burkhardt LAUFER, Joachim ZETTLER, Romy REIMANN
-
Patent number: D907765Type: GrantFiled: March 30, 2017Date of Patent: January 12, 2021Assignee: ASCENDIS PHARMA A/SInventor: Carsten Eriksen